In a whirlwind of market reactions, biotech stocks Argenx ( NASDAQ:ARGX ) and Immunovant ( NASDAQ:IMVT ) emerged as frontrunners on Thursday, propelled by disappointing results from Japanese rival Chugai Pharmaceutical. The contrast in fortunes underscores the high stakes and volatile nature of the biotech industry, where a single clinical trial outcome can send...
Argenx is another biotech stock setting up in a textbook breakout pattern.
Shares traded up through resistance Monday morning on good volume, but the move was ultimately held back by a nasty overall market.
ARGX still held up well, and will likely continue its advance higher.
Looking to place some longs on ARGX. Argenx SE operates as a biotechnology company. The Company develops antibody based therapies for the treatment of severe autoimmune diseases and cancer. argenx serves customers in the Netherlands and Belgium.n top 10: 10 8 25.0% 6 (0.35%) 6 (0.35%) 0.0%
Funds Holding: 185 170 8.82% 63 (3.7%) 55 (3.19%) 14.55%
13F shares: 28.505...
Will Argenx be Wall streets next Biotech unicorn? I am extremely bullish!
Biotech is booming business. Monoclonal antibodies are revolutionizing pharma industry.
Again great news for Argenx.
01feb2021
launches new global offering to raise funds after 'Go' decisions for CIDP treatment trials
www.argenx.com
www.argenx.com
02feb2021
Argenx raises $1 bln
...
After forming the gap at the market open , NASDAQ:ARGX has succeeded to close above the Red Line around the 206.5 .
IF it succeeds today or in an upcoming day to close with bullish strength considerably above the green line at around the 217 mark ,I think It is likely to continue up to around the 270-272 area even though price is now at an all time high...
ARGX: argenx SE
2020-05-26 01:00:00
argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis
The data showed a clinically meaningful and statistically significant benefit of ARGX-113 over placebo. In addition, ARGX-113 was found to have a favorable tolerability profile consistent with that observed in the Phase 1 study.
“These data demonstrate a rapid and sustained benefit in disease score after treatment with ARGX-113, supporting further development of...
Those who have the ability to ignore the noise and the roller coaster ride that the markets have brought upon us from early October to this day, you would be +80% on $ARGX. Nevertheless, if you were/are trading/playing it, it's a good play.
Whether it's politics or economics, there's way too many factors in play so all things are considered, -awareness for the...
if this thing can keep trending up and break 90 I may just have to take it out for a spin, to make gains and purely only for gains. Bullish baby please on a nightly and daily basis.
